KYMR

Kymera Therapeutics, Inc. Common Stock

85.04

USD

KYMR Earnings Reports

Positive Surprise Ratio

KYMR beat 6 of 22 last estimates.

27%

Next Report

Date of Next Report

May 07, 2026

Estimate for Q1 26 (Revenue/ EPS)

$8.82M

-$0.89

Implied change from Q4 25 (Revenue/ EPS)

+207.35%

-8.25%

Implied change from Q1 25 (Revenue/ EPS)

-60.07%

+8.54%

Kymera Therapeutics, Inc. Common Stock earnings per share and revenue

On Feb 26, 2026, KYMR reported earnings of -0.97 USD per share (EPS) for Q4 25, missing the estimate of -0.81 USD, resulting in a -19.43% surprise. Revenue reached 2.87 million, compared to an expected 15.35 million, with a -81.30% difference. The market reacted with a +4.80% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.89 USD, with revenue projected to reach 8.82 million USD, implying an decrease of -8.25% EPS, and increase of 207.35% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Liquidia Corporation Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.18

Actual

$0.15

Surprise

-18.48%

Legend Biotech Corporation - ADR

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.11

Actual

-$0.08

Surprise

+27.73%

BioNTech SE - ADR

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.32

Surprise

-72.12%

Kura Oncology, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.62

Actual

-$0.92

Surprise

-47.84%

CorMedix Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.83

Actual

$0.61

Surprise

-26.73%

ADC Therapeutics SA

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.04

Surprise

+85.39%

Contineum Therapeutics, Inc. Class A Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.49

Surprise

-18.41%

Atea Pharmaceuticals, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.56

Surprise

-5.44%

Coherus Oncology, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.35

Actual

-$0.34

Surprise

+4.76%

Anixa Biosciences, Inc.

Report Date

Mar 09, 2026 For Q1 26

Estimate

-$0.09

Actual

-$0.08

Surprise

+17.44%

FAQ

What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.97, missing estimates by -19.43%, and revenue of $2.87M, -81.3% below expectations.

How did the market react to Kymera Therapeutics, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 4.8%, changed from $90.68 before the earnings release to $95.03 the day after.

When is Kymera Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 07, 2026.

What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?

Based on 13 analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.89 and revenue of $8.82M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.